( September 17, 2026, 8:28 AM EDT) -- SAN FRANCISCO — Pfizer Inc. and Global Blood Therapeutics have agreed to fund up to $750,000 in reimbursements for certain out-of-pocket purchases of the sickle cell disease drug Oxbryta to settle a proposed class action alleging that consumers would not have bought the medication had they known that it was ineffective, according to an unopposed motion for preliminary approval filed in a California federal court....